DOCSLIB.ORG

Q Which Medications Work Best for Menorrhagia?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Q Which Medications Work Best for Menorrhagia? Evidence-based answers from the Family Physicians Inquiries Network CLINICAL INQUIRIES ONLINE EXCLUSIVE Allison Lale, MD, MPH; Elise Halajian, DO; Rick Q Which medications work best Guthmann, MD, MPH Advocate Illinois Masonic Medical Center, Chicago for menorrhagia? Joan Nashelsky, MLS Family Physicians Inquiries Network, Iowa City EVIDENCE-BASED ANSWER ASSISTANT EDITOR Four medications have been without reporting MBL. Gary Kelsberg, MD Valley Family Medicine A shown to reduce menstrual No studies compared all effective med- Residency, University of blood loss (MBL) significantly in ical therapies against one another. In head- Washington at Valley in placebo-controlled randomized controlled to-head comparisons, women were more Renton trials (RCTs): the levonorgestrel-releasing likely to experience improvement with the intrauterine system (LNG-IUS), tranexam- LNG-IUS than with tranexamic acid (num- ic acid, nonsteroidal anti-inflammatory ber needed to treat [NNT] = 2 to 6). Both drugs (NSAIDs), and danazol, a synthetic treatments are superior to NSAIDs. Dan- steroid (strength of recommendation: A, azol is also more efficacious than NSAIDs, meta-analyses of RCTs). but its use is limited by its adverse effects, A single trial showed that the LNG- including teratogenicity. IUS reduced MBL by about 100 mL, com- No placebo-controlled trials have pared with placebo. In a meta-analysis of studied oral contraceptive pills (OCPs) or 4 placebo-controlled RCTs, tranexamic acid oral progesterone to treat menorrhagia. reduced MBL by about 53 mL, roughly a However, multiple comparative RCTs have 40% to 50% decrease. The 8 NSAID trials (5 demonstrated that these commonly pre- mefenamic acid, 2 naproxen, 1 ibuprofen) scribed medications significantly decrease demonstrated effectiveness, but the effect MBL. Trials have shown the reduction to size is difficult to quantify. The single dan- be inferior to LNG-IUS and danazol and azol RCT used a subjective scoring system equivalent to NSAIDs. Evidence summary bination or progesterone-only pills. All of the A 2015 Cochrane review of the LNG-IUS for trials excluded women with palpable or large menorrhagia included 1 placebo-controlled (> 5 cm) fibroids. In 3 trials (2 against OCPs RCT; most of the remaining 21 RCTs com- and 1 against a 10-day course of oral proges- pared the LNG-IUS to invasive procedures terone), the LNG-IUS decreased MBL more such as endometrial ablation or hysterecto- than OCPs did. A fourth trial found LNG- my.1 The placebo-controlled trial compared IUS comparable to oral progesterone dosed the LNG-IUS with placebo in 40 women on 3 times a day from Day 5 to Day 26 of each anticoagulation therapy and found a mean menstrual cycle. beneficial difference of 100 mL (95% confi- A recent large RCT (571 patients) that dence interval [CI], –116 to –83) using a sub- compared LNG-IUS with usual medical treat- jective pictorial blood assessment chart. ment (mefenamic acid [MFA], tranexamic acid, norethindrone, OCPs, progesterone-only Women are less likely to withdraw pill, medroxyprogesterone acetate injection) from LNG-IUS treatment found women significantly less likely to with- Four trials (379 patients) included in the Co- draw from LNG-IUS at 2 years (relative risk chrane review compared LNG-IUS with com- [RR] = 0.58; 95% CI, 0.49-0.70).2 CONTINUED MDEDGE.COM/FAMILYMEDICINE VOL 69, NO 7 | SEPTEMBER 2020 | THE JOURNAL OF FAMILY PRACTICE E11 CLINICAL INQUIRIES Estrogen and progestin contraceptives Different NSAIDs, significantly reduce bleeding equivalent efficacy In addition to the trials in the 2015 Cochrane A 2013 Cochrane review of 18 RCTs includ- review comparing OCPs with LNG-IUS, a ed 8 (84 patients) that compared NSAIDs 2009 Cochrane review included a single (5 MFA, 2 naproxen, 1 ibuprofen) with place- 2-month crossover trial of 45 patients.3 This bo.5 In 6 trials, NSAIDs produced a significant RCT compared OCPs with naproxen, MFA, reduction in MBL compared with placebo, and danazol to treat heavy menstrual bleed- although most were crossover trials that ing (assessed using the alkaline haematin couldn’t be compiled into the meta-analysis. method). One trial (11 patients) showed a mean Researchers didn’t analyze the data us- reduction of 124 mL (95% CI, 62-186 mL) ing intention-to-treat. No group was found to in the MFA group. In another trial, women be superior. The OCP group (6 women) had were less likely to report no improvement a 43% reduction in MBL over baseline (no P in the MFA group than in the placebo group value reported). (odds ratio [OR] = 0.08; 95% CI, 0.03-0.18). No NSAID had significantly higher efficacy than Tranexamic acid outperforms the others. oral progesterone and NSAIDs but not ... Danazol was superior to NSAIDs in a A 2018 Cochrane meta-analysis of 13 RCTs meta-analysis of 3 trials (79 patients) with In head-to-head (1312 patients) of antifibrinolytics for re- a mean difference of 45 mL (95% CI, 19-71 comparisons, productive-age women with regular heavy mL), as was tranexamic acid in a single trial women were periods and no known underlying pathol- (48 patients) with a mean difference of 73 mL 5 more likely to ogy included 4 RCTs (565 patients) that (95% CI, 22-124 mL). Comparisons with 4 improve with used placebo as a comparator. Therapy with OCPs, oral progesterone, and an older the LNG-IUS tranexamic acid decreased blood loss by model of LNG-IUS showed no significant than tranexamic 53 mL per cycle (95% CI, 44-63 mL), a 40% to differences. The most common adverse -ef 50% improvement compared with placebo. fects were gastrointestinal. acid for reducing Three of the RCTs (271 patients) reported the menstrual blood percent of women improving on tranexam- Danazol linked to weight gain loss. ic acid as 43% to 63%, compared with and other adverse effects 11% for placebo, resulting in an NNT of 2 A 2010 Cochrane review evaluated 9 RCTs, to 3. including 1 (66 patients) comparing dan- One trial (46 patients) found tranexamic azol 200 mg with placebo that showed a sig- acid superior to luteal phase oral progester- nificant decrease in subjectively assessed one, and another study (48 patients) demon- MBL in the danazol group.6 The study, which strated superiority to NSAIDs, with a mean only 22 women finished, didn’t address decrease in MBL of 86 mL compared with intention-to-treat and used an unidentified 43 mL (P < .0027). scoring system. Patients also reported a sig- On the other hand, tranexamic acid nificant 6.7-kg weight gain (95% CI, 1-12.4) compared unfavorably with LNG-IUS (1 RCT, after 3 months of treatment. 42 patients), showing a lower likelihood of In addition to the 2013 meta-analysis improvement (RR = 0.43; 95% CI, 0.24-0.77). showing danazol to be superior to NSAIDs, Whereas 85% of women improved with LNG- several studies6 compared danazol favorably IUS, only 20% to 65% of women improved with oral progesterone, although not all re- with tranexamic acid (NNT = 2 to 6). sults reached significance. One study (37 pa- No statistical difference was found in tients) showed that women were more likely gastrointestinal adverse effects, headache, to rate the efficacy of danazol as moderate or vaginal dryness, or dysmenorrhea.4 Only high compared with progesterone (OR = 4.3; 1 thromboembolic event occurred in the 95% CI, 1.1-17.0), but the mean difference in 2 studies that reported this outcome, a known MBL (–36 mL; 95% CI, −102 to 31 mL) wasn’t risk that prohibits its concomitant use with statistically significant. combination OCPs. Of note, both a meta-analysis of 4 of the E12 THE JOURNAL OF FAMILY PRACTICE | SEPTEMBER 2020 | VOL 69, NO 7 studies (117 patients) and another study com- Editor’s takeaway paring danazol with NSAIDs (20 patients) I was taught to use combination OCPs as first- found significantly more adverse effects in line treatment for menorrhagia, but better evi- the danazol group. Commonly reported ad- dence supports using any of these 4: LNG-IUS, verse effects were acne, weight gain, head- tranexamic acid, danazol, or NSAIDs. In the ache, nausea, and tiredness. absence of clear evidence demonstrating dif- ferences in efficacy, I would use them in the reverse order for cost-effectiveness reasons. JFP Recommendations A comparative effectiveness review by the References Agency for Healthcare Research and Qual- 1. Lethaby A, Hussain M, Rishworth JR, et al. Progesterone or pro- gesterone-releasing intrauterine systems for heavy menstrual ity concluded that evidence showed efficacy bleeding. Cochrane Database Syst Rev. 2015;(4):CD002126. for 4 primary care interventions for heavy cy- 2. Gupta J, Kai J, Middleton L, et al. Levonorgestrel intrauterine system versus medical therapy for menorrhagia N Engl J Med. clic bleeding: LNG-IUS, NSAIDs, tranexamic 2013;368:128-137. 7 acid, and combination OCPs. 3. Farquhar C, Brown J. Oral contraceptive pill for heavy menstrual The United Kingdom’s National Institute bleeding. Cochrane Database Syst Rev. 2009;(4):CD000154. 4. Bryant-Smith AC, Lethaby A, Farquhar C, et al. Antifibrinolyt- for Health Care and Excellence (NICE) rec- ics for heavy menstrual bleeding. Cochrane Database Syst Rev. ommends pharmaceutical treatment when 2018;(4):CD000249. 5. Lethaby A, Duckitt K, Farquhar C. Non-steroidal anti-inflamma- no structural or histologic abnormality is tory drugs for heavy menstrual bleeding. Cochrane Database Syst present or when fibroids are < 3 cm in diam- Rev. 2013;(1):CD000400. 6. Beaumont HH, Augood C, Duckitt K, et al. Danazol for heavy eter.8 NICE advises considering pharmaceu- menstrual bleeding. Cochrane Database Syst Rev. 2010;(1): tical treatments in the following order: first, CD00107. 7. Hartmann KE, Jerome RN, Lindegren ML, et al. Primary Care LNG-IUS if long-term use (at least 12 months) Management of Abnormal Uterine Bleeding.
Load more

Recommended publications
  • Suitability of Immobilized Systems for Microbiological Degradation of Endocrine Disrupting Compounds
    molecules Review Suitability of Immobilized Systems for Microbiological Degradation of Endocrine Disrupting Compounds Danuta Wojcieszy ´nska , Ariel Marchlewicz and Urszula Guzik * Institute of Biology, Biotechnology and Environmental Protection, Faculty of Natural Science, University of Silesia in Katowice, Jagiello´nska28, 40-032 Katowice, Poland; [email protected] (D.W.); [email protected] (A.M.) * Correspondence: [email protected]; Tel.: +48-3220-095-67 Academic Editors: Urszula Guzik and Danuta Wojcieszy´nska Received: 10 September 2020; Accepted: 25 September 2020; Published: 29 September 2020 Abstract: The rising pollution of the environment with endocrine disrupting compounds has increased interest in searching for new, effective bioremediation methods. Particular attention is paid to the search for microorganisms with high degradation potential and the possibility of their use in the degradation of endocrine disrupting compounds. Increasingly, immobilized microorganisms or enzymes are used in biodegradation systems. This review presents the main sources of endocrine disrupting compounds and identifies the risks associated with their presence in the environment. The main pathways of degradation of these compounds by microorganisms are also presented. The last part is devoted to an overview of the immobilization methods used for the purposes of enabling the use of biocatalysts in environmental bioremediation. Keywords: EDCs; hormones; degradation; immobilization; microorganisms 1. Introduction The development of modern tools for the separation and identification of chemical substances has drawn attention to the so-called micropollution of the environment. Many of these contaminants belong to the emergent pollutants class. According to the Stockholm Convention they are characterized by high persistence, are transported over long distances in the environment through water, accumulate in the tissue of living organisms and can adversely affect them [1].
    [Show full text]
  • SPIRONOLACTONE Spironolactone – Oral (Common Brand Name
    SPIRONOLACTONE Spironolactone – oral (common brand name: Aldactone) Uses: Spironolactone is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It is also used to treat swelling (edema) caused by certain conditions (e.g., congestive heart failure) by removing excess fluid and improving symptoms such as breathing problems. This medication is also used to treat low potassium levels and conditions in which the body is making too much of a natural chemical (aldosterone). Spironolactone is known as a “water pill” (potassium-sparing diuretic). Other uses: This medication has also been used to treat acne in women, female pattern hair loss, and excessive hair growth (hirsutism), especially in women with polycystic ovary disease. Side effects: Drowsiness, lightheadedness, stomach upset, diarrhea, nausea, vomiting, or headache may occur. To minimize lightheadedness, get up slowly when rising from a seated or lying position. If any of these effects persist or worsen, notify your doctor promptly. Tell your doctor immediately if any of these unlikely but serious side effects occur; dizziness, increased thirst, change in the amount of urine, mental/mood chances, unusual fatigue/weakness, muscle spasms, menstrual period changes, sexual function problems. This medication may lead to high levels of potassium, especially in patients with kidney problems. If not treated, very high potassium levels can be fatal. Tell your doctor immediately if you notice any of the following unlikely but serious side effects: slow/irregular heartbeat, muscle weakness. Precautions: Before taking spironolactone, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies.
    [Show full text]
  • Homeopathy and Psychological Therapies
    Entry Homeopathy and Psychological Therapies Davide Donelli * and Michele Antonelli AUSL-IRCCS Reggio Emilia, 42122 Reggio Emilia, Italy; [email protected] * Correspondence: [email protected] Definition: Homeopathy is a popular, although highly debated, medicinal practice based on the administration of remedies in which active substances are so diluted that no detectable trace of them remains in the final product. This hypothesis paper aims to outline a possible reinterpreta- tion of homeopathy in the light of psychological therapies in order to improve its clinical safety and sustainability. Keywords: homeopathy; psychology; reinterpretation; hypothesis 1. Introduction Homeopathy is a popular, although highly debated, medicinal practice. In Italy, for ex- ample, it is estimated that, even if with a slightly declining trend, around 4.1% of the entire population (almost 2.5 million people) occasionally or regularly seeks homeopathic care, and these data, collected in 2013, suggest that homeopathy is the most used Complemen- tary and Alternative Medicine (CAM) by Italians [1]. Epidemiological studies aimed to assess the worldwide prevalence of homeopathy use have reported similar data for other high-income countries [2]. Homeopathy was first invented by the German doctor Samuel Hahnemann (1755–1843), and it is based on the administration of remedies in which active substances are so diluted that no detectable trace of them remains in the final product [3]. In his empirical studies, Citation: Donelli, D.; Antonelli, M. Hahnemann reported that the self-administration of a common antimalarial medicinal Homeopathy and Psychological Ther- plant (Cinchona) resulted in the occurrence of the same symptoms of malaria, but to a Encyclopedia 2021 1 apies.
    [Show full text]
  • Ocps) Used in the NM Family Planning Program (FPP
    The following slides are intended to familiarize nurses and clinicians with oral contraceptive pills (OCPs) used in the NM Family Planning Program (FPP). The FPP does not intend for this information to supersede the Family Planning Protocol particularly on the requirement for Public Health Nurses in the Public Health Offices to consult a clinician as stated in the Protocol when in doubt or if it is necessary to switch the client’s OCP type. 1 2 Combined oral contraceptives (COCs) contain two hormones; estrogen and progestin. In general, any combined OCP is good for most women who are eligible to take estrogen according to the CDC U.S. Medical Eligibility Criteria (MEC). Once again, refer to the US MEC chart to find out if OCP is a suitable choice for clients with specific health conditions. To learn a little bit about what each hormone does, the FPP is providing the following summary: Estrogen: provides endometrial stability = menstrual cycle control. A higher estrogen dose increases the venous thromboembolism (VTE) or clot risk but OCP clot risk is still less harmful than the clot risk related to pregnancy and giving birth. Progestin: provides most of the contraceptive effect by ‐Preventing luteinizing hormone (LH) surge /ovulation ‐Thickening the cervical mucus to prevent sperm entry. Two major OCP formations are available. Monophasic: There is only one dose of estrogen and progestin in each active pill in the packet; and Multiphasic: There are varying doses of hormones, particularly progestin in the active pills. 3 Section 3 of the FPP Protocol contains the OCP Substitute Table, which groups OCPs into 6 classes according to the estrogen dosage, the type of progestin and the formulations.
    [Show full text]
  • Nicotine and Behavioral Markers of Risk for Schizophrenia: a Double-Blind, Placebo- Controlled, Cross-Over Study Lana Dépatie, M.Sc., Gillian A
    Nicotine and Behavioral Markers of Risk for Schizophrenia: A Double-Blind, Placebo- Controlled, Cross-Over Study Lana Dépatie, M.Sc., Gillian A. O’Driscoll, Ph.D., Anne-Lise V. Holahan, B.Sc., Victoria Atkinson, R.N., Joseph X. Thavundayil, M.D., N. Ng Ying Kin, Ph.D., and Samarthji Lal, M.D. We investigated the effect of nicotine on three behavioral groups. A Drug ϫ Monitoring condition interaction (p Ͻ .01) markers of risk for schizophrenia: sustained attention on pursuit gain indicated that nicotine significantly (using the Continuous Performance Task (CPT)), increased pursuit gain in the no-monitoring condition in antisaccade performance, and smooth pursuit. Smooth patients and controls equally, but did not improve pursuit pursuit was investigated in two conditions, one in which in the monitoring condition. Thus, improvement in pursuit attention was enhanced (monitoring target changes) and may have been mediated via an effect on attention rather one in which attention was not enhanced (no monitoring). than by an effect on oculomotor function per se. In patients, Patients with schizophrenia (n ϭ 15) and controls (n ϭ 14) the magnitude of improvement in attention on nicotine was were given a 14-mg nicotine patch in a double-blind, correlated with the improvement on eye movement tasks. placebo-controlled, crossover design and plasma nicotine Thus, nicotine improves performance on both attention and concentrations were monitored. Nicotine concentrations oculomotor markers of risk for schizophrenia, possibly via were similar in both groups. A Group ϫ Drug interaction common mechanisms. (p Ͻ .02) on CPT hits indicated that nicotine improved [Neuropsychopharmacology 27:1056–1070, 2002] sustained attention in patients but not in controls.
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Estrogen Actions Throughout the Brain
    Estrogen Actions Throughout the Brain BRUCE MCEWEN Harold and Margaret Milliken Hatch Laboratory of Neuroendocrinology, The Rockefeller University, New York, New York 10021 ABSTRACT Besides affecting the hypothalamus and other brain areas related to reproduction, ovarian steroids have widespread effects throughout the brain, on serotonin pathways, catecholaminergic neurons, and the basal forebrain cholinergic system as well as the hippocampal formation, a brain region involved in spatial and declarative memory. Thus, ovarian steroids have measurable effects on affective state as well as cognition, with implications for dementia. Two actions are discussed in this review; both appear to involve a combination of genomic and nongenomic actions of ovarian hormones. First, regulation of the serotonergic system appears to be linked to the presence of estrogen- and progestin-sensitive neurons in the midbrain raphe as well as possibly nongenomic actions in brain areas to which serotonin neurons project their axons. Second, ovarian hormones regulate synapse turnover in the CA1 region of the hippocampus during the 4- to 5-day estrous cycle of the female rat. Formation of new excitatory synapses is induced by estradiol and involves N-methyl-D-aspartate (NMDA) receptors, whereas downregulation of these synapses involves intracellular progestin receptors. A new, rapid method of radioimmunocytochemistry has made possible the demonstration of synapse formation by labeling and quantifying the specific synaptic and dendritic molecules involved. Although NMDA receptor activation is required for synapse formation, inhibitory interneurons may play a pivotal role as they express nuclear estrogen receptor-alpha (ER␣). It is also likely that estrogens may locally regulate events at the sites of synaptic contact in the excitatory pyramidal neurons where the synapses form.
    [Show full text]
  • Demystifying the Placebo Effect
    City University of New York (CUNY) CUNY Academic Works All Dissertations, Theses, and Capstone Projects Dissertations, Theses, and Capstone Projects 9-2018 Demystifying the Placebo Effect Phoebe Friesen The Graduate Center, City University of New York How does access to this work benefit ou?y Let us know! More information about this work at: https://academicworks.cuny.edu/gc_etds/2775 Discover additional works at: https://academicworks.cuny.edu This work is made publicly available by the City University of New York (CUNY). Contact: [email protected] DEMYSTIFYING THE PLACEBO EFFECT by PHOEBE FRIESEN A dissertation submitted to the Graduate Faculty in Philosophy in partial fulfillment of the requirements for the degree of Doctor of Philosophy, The City University of New York 2018 © 2018 PHOEBE FRIESEN All Rights Reserved ii Demystifying the Placebo Effect by Phoebe Friesen This manuscript has been read and accepted for the Graduate Faculty in Philosophy in satisfaction of the dissertation requirement for the degree of Doctor of Philosophy. ___________ ____________________________________ Date [Peter Godfrey-Smith] Chair of Examining Committee ___________ ____________________________________ Date [Nickolas Pappas ] Executive Office Supervisory Committee: Peter Godfrey-Smith Jesse Prinz John Greenwood THE CITY UNIVERSITY OF NEW YORK iii ABSTRACT Demystifying the Placebo Effect by Phoebe Friesen Advisor: Peter Godfrey-Smith This dissertation offers a philosophical analysis of the placebo effect. After offering an overview of recent evidence concerning the phenomenon, I consider several prominent accounts of the placebo effect that have been put forward and argue that none of them are able to adequately account for the diverse instantiations of the phenomenon. I then offer a novel account, which suggests that we ought to think of the placebo effect as encompassing three distinct responses: conditioned placebo responses, cognitive placebo responses, and network placebo responses.
    [Show full text]
  • Anabolic Steroids/Androgens Pa Summary
    ANABOLIC STEROIDS/ANDROGENS PA SUMMARY PREFERRED Anadrol-50, Danazol, Fluoxymesterone, Methitest, Oxandrolone, Testosterone Cypionate Injection, Testosterone Enanthate Injection NON-PREFERRED Android, Testred LENGTH OF AUTHORIZATION: Varies NOTE: All preferred and non-preferred agents require prior authorization. See PA criteria labeled “Topical Testosterone” for Androderm, Androgel, Striant, and Testim. The criteria details below are for the outpatient pharmacy program. If an injectable medication is being administered in a physician’s office then the criteria information below does not apply. Instead, the physician’s office must bill this drug through the DCH physician’s injectable program and not the outpatient pharmacy program. Information regarding the physician’s injectable program can be located at www.mmis.georgia.gov. PA CRITERIA: For Anadrol-50 Approvable for the following diagnoses: anemia caused by deficient red blood cell production, acquired or congenital aplastic anemia, myelofibrosis, hypoplastic anemia due to administration of myelotoxic drugs Also approvable for HIV or AIDS wasting when significant weight loss is documented in members currently receiving nutritional support For Danazol Approvable for the following diagnoses: endometriosis, fibrocystic breast disease, hereditary angioedema For Fluoxymesterone, Methyltestosterone (Android, Methitest, Testred), Testosterone Cypionate or Enanthate Injection Approvable in male members 12 years of age or older for the following diagnoses: primary hypogonadism, secondary
    [Show full text]
  • Placebo-Controlled Trials of New Drugs: Ethical Considerations
    Reviews/Commentaries/Position Statements COMMENTARY Placebo-Controlled Trials of New Drugs: Ethical Considerations DAVID ORENTLICHER, MD, JD als, placebo controls are not appropriate when patients’ health would be placed at significant risk (8–10). A placebo- controlled study for a new hair- uch controversy exists regarding sufficiently more effective than placebo to thickening agent could be justified; a the ethics of placebo-controlled justify its use. Finally, not all established placebo-controlled study for patients M trials in which an experimental therapies have been shown to be superior with moderate or severe hypertension therapy will compete with an already es- to placebo. If newer drugs are compared would not be acceptable (11). Similarly, if tablished treatment (or treatments). In with the unproven existing therapies, an illness causes problems when it goes such cases, argue critics, patients in the then patients may continue to receive untreated for a long period of time, a 52- control arm of the study should receive an drugs that are harmful without being week study with a placebo control is accepted therapy rather than a placebo. helpful. much more difficult to justify than a By using an active and effective drug, the Moreover, say proponents of placebo 6-week study (12). control patients would not be placed at controls, patients can be protected from When David S.H. Bell (13) explains risk for deterioration of their disease, and harm by “escape” criteria, which call for why placebo controls are unacceptable the study would generate more meaning- withdrawal from the trial if the patient for new drugs to treat type 2 diabetes, he ful results for physicians.
    [Show full text]
  • Homeopathy Is Marketed As a Safe, Natural and Holistic Treatment for a Range of Ailments and Illnesses, Including Another Way of Saying
    sense about... sense about... sense about... sense about... sense about... sense about...Homeo sense about... sense about...path sense about...yyy sense about... sense about... sense about... sense about... sense about... sense about... sense about... Homeopathy is marketed as a safe, natural and holistic treatment for a range of ailments and illnesses, including Another way of saying... arthritis, asthma, depression, eczema, diarrhoea, hayfever, 8lacebo 999 a prescription that is inert; that is, it does nothing, headaches, insomnia and toothache. Homeopathic products and like a sugar pill or water. From the Latin, 1 will please.) services have become a large industry. 8lacebo effect 9 an effect, biological, biochemical or Despite this, it has not been embraced by medical science. The physiological, that emerges from an inert treatment because scientific evidence shows that homeopathy acts only as a the patient believes it will work. See page 2 for how placebos work.) placebo and there is no scientific explanation of how it could work any other way. Not to be confused... HomeoHomeopathpathpathicic principles 8roven 999 0proving( is the method homeopaths use to determine the symptoms a substance causes with a view to Homeopathy is based on two beliefs: 1) like cures like; and 2) treating diseases with similar symptoms); after the process a the smaller the dose the more potent the cure. First, homeopaths substance is said to be 0proven(. Scientists use 0proven( to choose a substance that causes the same symptoms as the describe a statement that is, by logic, necessarily true. disease they want to treat. For example, the runny nose and watery eyes of a cold can be recreated by inhaling onion fumes, human and animal waste, dead plants, bacteria and minerals; it so onion juice can form the basis of a homeopathic preparation.
    [Show full text]
  • Illinois Medicaid Preferred Drug List
    Illinois Medicaid Preferred Drug List Effective January 1, 2020 (Updated January 27, 2020) ▪ The Preferred Drug List (PDL) has products listed in groups by drug class, drug name, dosage form, and PDL status ▪ Multi-source drugs are listed by both brand and generic names when applicable ▪ ADHD Agents: Prior authorization required for participants under 6 years of age and participants 19 years of age and older ▪ Spiriva AER 1.25mcg: Prior authorization NOT required for participants ages 6-17 years ▪ Budesonide: Prior authorization NOT required for participants age 7 years and under ▪ Anticonvulsants: Prior authorization NOT required for non-preferred epilepsy agents for those participants with a diagnosis of epilepsy or seizure disorder in Department records ▪ Antipsychotics: Prior authorization required for participants under 8 years of age and long-term care residents ▪ For drugs not found on this list, go to the drug search engine at: www.ilpriorauth.com Page 1 of 92 DOSAGE DRUG CLASS DRUG NAME PDL STATS FORM ADHD / ANTI-NARCOLEPSY AGENTS : AMPHETAMINES ADZENYS ER SUER NON_PREFERRED AMPHETAMINE ER SUER NON_PREFERRED DYANAVEL XR SUER NON_PREFERRED ADZENYS XR-ODT TBED NON_PREFERRED AMPHETAMINE SULFATE TABS NON_PREFERRED EVEKEO TABS NON_PREFERRED EVEKEO ODT TBDP NON_PREFERRED DEXEDRINE CP24 NON_PREFERRED DEXTROAMPHETAMINE SULFATE ER CP24 NON_PREFERRED DEXTROAMPHETAMINE SULFATE SOLN NON_PREFERRED PROCENTRA SOLN NON_PREFERRED DEXTROAMPHETAMINE SULFATE TABS NON_PREFERRED ZENZEDI TABS NON_PREFERRED VYVANSE CAPS PREFERRED VYVANSE CHEW PREFERRED
    [Show full text]